Antimyelin antibody in multiple sclerosis: no change during immunosuppression
AUTOR(ES)
Wilkerson, L. D.
RESUMO
We studied retrospectively levels of antimyelin antibody in a group of 13 multiple sclerosis patients who underwent a clinical trial of long-term, high dose (2.0-4.5 mg/kg/day) azathiaprine therapy. In apparent contrast with collagen vascular disease associated with antitissue antibody, azathiaprine therapy was not associated with significant change in titres of antimyelin antibody. Variation of titre of antimyelin antibody in apparent association with disease activity continued during therapy. No significant changes occurred in levels of serum immunoglobulins.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=492860Documentos Relacionados
- Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.
- MULTIPLE SCLEROSIS: A REAPPRAISAL
- Anti‐aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic–spinal multiple sclerosis without long spinal cord lesions and anti‐aquaporin 4 antibody
- Multiple sclerosis: looking beyond autoimmunity
- Multiple sclerosis: mortality in Scotland 1974-80.
